RELMADA THERAPEUTICS, INC. Increase (Decrease) in Other Current Assets
RELMADA THERAPEUTICS, INC. (RLMD) reported Increase (Decrease) in Other Current Assets of $256.19 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2022-08-11
- RELMADA THERAPEUTICS, INC. increase (decrease) in other current assets for the quarter ending 2019-03-31 was $25.00K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other current assets for the quarter ending 2013-08-31 was $0.00.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other current assets for the quarter ending 2013-05-31 was $0.00.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other current assets for the quarter ending 2013-02-28 was $0.00.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other current assets for fiscal 2013 was $3.00K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other current assets for fiscal 2012 was -$3.00K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2022-06-30 | $256.19K 10-Q · filed 2022-08-11 | |||
| 2019-03-31 | $25.00K 10-Q · filed 2020-05-15 | |||
| 2013-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | $0.00 derived: sum of 2 quarters · filed 2013-12-16 | $0.00 derived: sum of 3 quarters · filed 2014-04-15 | $3.00K 10-K · filed 2013-12-16 |
| 2013-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-12 | $0.00 derived: sum of 2 quarters · filed 2014-04-15 | $3.00K 10-Q · filed 2013-07-12 | |
| 2013-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-15 | $3.00K 10-Q · filed 2014-04-15 | ||
| 2012-11-30 | $3.00K 10-Q · filed 2014-01-13 | |||
| 2012-08-31 | -$3.00K 10-K · filed 2013-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |